Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and NK cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. A small molecule inhibitor of Lck is expected to be useful in the treatment of T cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection. In this paper, we describe the synthesis, structure-activity relationships, and pharmacological characterization of 2-aminopyrimidine carbamates, a new class of compounds with potent and selective inhibition of Lck. The most promising compound of this series, 2,6-dimethylphenyl 2-((3,5-bis(methyloxy)-4-((3-(4-methyl-1-piperazinyl)propyl)oxy)phenyl)amino)-4-pyrimidinyl(2,4-bis(methyloxy)phenyl)carbamate (43) exhibits good activity when evaluated in in vitro assays and in an in vivo model of T cell activation.
Martin
Matthew W
MW
Department of Chemistry Research and Discovery, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, USA. matmarti@amgen.com
Newcomb
John
J
Nunes
Joseph J
JJ
McGowan
David C
DC
Armistead
David M
DM
Boucher
Christina
C
Buchanan
John L
JL
Buckner
William
W
Chai
Lilly
L
Elbaum
Daniel
D
Epstein
Linda F
LF
Faust
Theodore
T
Flynn
Shaun
S
Gallant
Paul
P
Gore
Anu
A
Gu
Yan
Y
Hsieh
Faye
F
Huang
Xin
X
Lee
Josie H
JH
Metz
Daniela
D
Middleton
Scot
S
Mohn
Deanna
D
Morgenstern
Kurt
K
Morrison
Michael J
MJ
Novak
Perry M
PM
Oliveira-dos-Santos
Antonio
A
Powers
David
D
Rose
Paul
P
Schneider
Stephen
S
Sell
Stephanie
S
Tudor
Yanyan
Y
Turci
Susan M
SM
Welcher
Andrew A
AA
White
Ryan D
RD
Zack
Debra
D
Zhao
Huilin
H
Zhu
Li
L
Zhu
Xiaotian
X
Ghiron
Chiara
C
Amouzegh
Patricia
P
Ermann
Monika
M
Jenkins
James
J
Johnston
David
D
Napier
Spencer
S
Power
Eoin
E
D000284:Administration, Oral; D000631:Aminopyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001682:Biological Availability; D002219:Carbamates / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D018360:Crystallography, X-Ray; D006801:Humans; D066298:In Vitro Techniques; D019169:Jurkat Cells; D008213:Lymphocyte Activation; D007959:Lymphocyte Culture Test, Mixed; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / Q000037:antagonists & inhibitors*; D051379:Mice; D008807:Mice, Inbred BALB C; D008958:Models, Molecular; D015394:Molecular Structure; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013329:Structure-Activity Relationship; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
C513371:2,6-dimethylphenyl 2-((3,5-bis(methyloxy)-4-((3-(4-methyl-1-piperazinyl)propyl)oxy)phenyl)amino)-4-pyrimidinyl(2,4-bis(methyloxy)phenyl)carbamate; D000631:Aminopyridines; D000893:Anti-Inflammatory Agents; D002219:Carbamates; D011743:Pyrimidines; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck)